<?xml version="1.0" encoding="UTF-8"?>
<p>The sudden outbreak of Coronavirus Disease 2019 (COVID-19), stemming from a novel coronavirus originating from Wuhan, China, has grown into a global pandemic as the third major outbreak of the virulent coronavirus family after Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).
 <sup>
  <xref rid="bibr1-2049936120947517" ref-type="bibr">1</xref>
 </sup> Despite radical containment efforts, the SARS Coronavirus 2 (CoV 2) continues to spread globally. Currently, therapeutic tactics are only supportive as there are no proven pharmacological agents active against the virus.
 <sup>
  <xref rid="bibr2-2049936120947517" ref-type="bibr">2</xref>
 </sup> International efforts are focussed on searching for effective therapies to counter the diseaseâ€™s effects. One strategy is to search for Nobel agents by repurposing older drugs with known antiviral activity that have been studied in the past.
 <sup>
  <xref rid="bibr3-2049936120947517" ref-type="bibr">3</xref>
 </sup> In this regard, chloroquine (CQ) and hydroxychloroquine (HCQ) have garnered much attention as they were well studied during previous coronavirus epidemics with SARS and MERS.
 <sup>
  <xref rid="bibr4-2049936120947517" ref-type="bibr">4</xref>
 </sup>
</p>
